Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.

Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

2.

Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.

Ingle JN, Kalari KR, Momozawa Y, Kubo M, Furukawa Y, Shepherd LE, Ellis MJ, Goss PE, Barman P, Carlson EE, Sinnwell JP, Tang X, Goetz MP, Chen BE, Cairns J, Weinshilboum RM, Wang L.

Pharmacogenet Genomics. 2019 Oct;29(8):183-191. doi: 10.1097/FPC.0000000000000382.

PMID:
31211741
3.

Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.

Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN.

J Clin Oncol. 2019 Aug 1;37(22):1982-1983. doi: 10.1200/JCO.19.00504. Epub 2019 Jun 18. No abstract available.

PMID:
31211604
4.

Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.

Hunt KN, Conners AL, Goetz MP, O'Connor MK, Suman V, Kalari K, Weinshilboum R, Wang L, Carter J, McLaughlin S, Aspitia AM, Gray R, Northfelt D, Boughey JC.

AJR Am J Roentgenol. 2019 Oct;213(4):932-943. doi: 10.2214/AJR.18.20628. Epub 2019 Jun 5.

PMID:
31166752
5.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
6.

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy.

Al-Hilli Z, Choong G, Keeney MG, Visscher DW, Ingle JN, Goetz MP, Jakub JW.

Breast Cancer Res Treat. 2019 Aug;176(3):709-716. doi: 10.1007/s10549-019-05264-2. Epub 2019 May 22.

PMID:
31119569
7.

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Cairns J, Ingle JN, Kalari KR, Shepherd LE, Kubo M, Goetz MP, Weinshilboum RM, Wang L.

Breast Cancer Res. 2019 Apr 3;21(1):47. doi: 10.1186/s13058-019-1130-3.

8.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Mar 23. pii: mdz076. doi: 10.1093/annonc/mdz076. [Epub ahead of print]

PMID:
30903140
9.

NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2019 Feb;17(2):118-126. doi: 10.6004/jnccn.2019.0009.

PMID:
30787125
10.

The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer.

Zhuang Y, Ly RC, Frazier CV, Yu J, Qin S, Fan XY, Goetz MP, Boughey JC, Weinshilboum R, Wang L.

Cancer Metab. 2019 Jan 24;7:1. doi: 10.1186/s40170-018-0193-4. eCollection 2019.

11.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP.

NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.

12.

PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.

Kalari KR, Sinnwell JP, Thompson KJ, Tang X, Carlson EE, Yu J, Vedell PT, Ingle JN, Weinshilboum RM, Boughey JC, Wang L, Goetz MP, Suman V.

JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.18.00012.

13.

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2.

Dudenkov TM, Liu D, Cairns J, Devarajan S, Zhuang Y, Ingle JN, Buzdar AU, Robson ME, Kubo M, Batzler A, Barman P, Jenkins GD, Carlson EE, Goetz MP, Northfelt DW, Moreno-Aspitia A, Desta Z, Reid JM, Kalari KR, Wang L, Weinshilboum RM.

Clin Pharmacol Ther. 2019 Jul;106(1):219-227. doi: 10.1002/cpt.1359. Epub 2019 Mar 18.

14.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy.

Di Leo A, O'Shaughnessy J, Sledge GW Jr, Martin M, Lin Y, Frenzel M, Hardebeck MC, Smith IC, Llombart-Cussac A, Goetz MP, Johnston S.

NPJ Breast Cancer. 2018 Dec 18;4:41. doi: 10.1038/s41523-018-0094-2. eCollection 2018.

15.

ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.

Reese JM, Bruinsma ES, Nelson AW, Chernukhin I, Carroll JS, Li Y, Subramaniam M, Suman VJ, Negron V, Monroe DG, Ingle JN, Goetz MP, Hawse JR.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9580-E9589. doi: 10.1073/pnas.1807751115. Epub 2018 Sep 26.

16.

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.

Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:65-77. doi: 10.1200/EDBK_200715. Review.

PMID:
30231328
17.

Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway.

Kurmi K, Hitosugi S, Yu J, Boakye-Agyeman F, Wiese EK, Larson TR, Dai Q, Machida YJ, Lou Z, Wang L, Boughey JC, Kaufmann SH, Goetz MP, Karnitz LM, Hitosugi T.

Cell Metab. 2018 Dec 4;28(6):833-847.e8. doi: 10.1016/j.cmet.2018.08.008. Epub 2018 Aug 30.

PMID:
30174304
18.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.

Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.

Mol Cancer Ther. 2018 Nov;17(11):2462-2472. doi: 10.1158/1535-7163.MCT-18-0470. Epub 2018 Aug 30.

PMID:
30166399
19.

HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data.

Baheti S, Tang X, O'Brien DR, Chia N, Roberts LR, Nelson H, Boughey JC, Wang L, Goetz MP, Kocher JA, Kalari KR.

BMC Bioinformatics. 2018 Jul 17;19(1):271. doi: 10.1186/s12859-018-2260-9.

20.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group.

N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4.

21.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

22.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

23.

The development of endoxifen for breast cancer.

Goetz MP.

Clin Adv Hematol Oncol. 2018 Feb;16(2):102-105. No abstract available.

PMID:
29741509
24.

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

J Clin Invest. 2018 Jun 1;128(6):2376-2388. doi: 10.1172/JCI97924. Epub 2018 Apr 30.

25.

Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.

West DC, Kocherginsky M, Tonsing-Carter EY, Dolcen DN, Hosfield DJ, Lastra RR, Sinnwell JP, Thompson KJ, Bowie KR, Harkless RV, Skor MN, Pierce CF, Styke SC, Kim CR, de Wet L, Greene GL, Boughey JC, Goetz MP, Kalari KR, Wang L, Fleming GF, Györffy B, Conzen SD.

Clin Cancer Res. 2018 Jul 15;24(14):3433-3446. doi: 10.1158/1078-0432.CCR-17-2793. Epub 2018 Apr 10.

26.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
27.

Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity.

Kurmi K, Hitosugi S, Wiese EK, Boakye-Agyeman F, Gonsalves WI, Lou Z, Karnitz LM, Goetz MP, Hitosugi T.

Cell Rep. 2018 Feb 6;22(6):1365-1373. doi: 10.1016/j.celrep.2018.01.030.

28.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

29.

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).

Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C.

Breast Cancer Res Treat. 2018 May;169(1):1-7. doi: 10.1007/s10549-018-4662-9. Epub 2018 Jan 19. Review.

30.

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.

Haddad TC, D'Assoro A, Suman V, Opyrchal M, Peethambaram P, Liu MC, Goetz MP, Ingle JN.

Breast Cancer Res Treat. 2018 Apr;168(3):639-647. doi: 10.1007/s10549-017-4616-7. Epub 2017 Dec 30.

31.

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.

Reese JM, Bruinsma ES, Monroe DG, Negron V, Suman VJ, Ingle JN, Goetz MP, Hawse JR.

Oncotarget. 2017 Oct 11;8(57):96506-96521. doi: 10.18632/oncotarget.21787. eCollection 2017 Nov 14.

32.

Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.

Yu J, Qin B, Moyer AM, Sinnwell JP, Thompson KJ, Copland JA 3rd, Marlow LA, Miller JL, Yin P, Gao B, Minter-Dykhouse K, Tang X, McLaughlin SA, Moreno-Aspitia A, Schweitzer A, Lu Y, Hubbard J, Northfelt DW, Gray RJ, Hunt K, Conners AL, Suman VJ, Kalari KR, Ingle JN, Lou Z, Visscher DW, Weinshilboum R, Boughey JC, Goetz MP, Wang L.

Breast Cancer Res. 2017 Dec 6;19(1):130. doi: 10.1186/s13058-017-0920-8.

33.

Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB.

Oncotarget. 2017 Sep 1;8(53):91803-91816. doi: 10.18632/oncotarget.20610. eCollection 2017 Oct 31.

34.

A comprehensive analysis of breast cancer microbiota and host gene expression.

Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP, Kalari KR.

PLoS One. 2017 Nov 30;12(11):e0188873. doi: 10.1371/journal.pone.0188873. eCollection 2017.

35.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

36.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

37.
38.

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.

Peethambaram PP, Hoskin TL, Day CN, Goetz MP, Habermann EB, Boughey JC.

NPJ Breast Cancer. 2017 Oct 19;3:41. doi: 10.1038/s41523-017-0044-4. eCollection 2017.

39.

Skeletal and Uterotrophic Effects of Endoxifen in Female Rats.

Gingery A, Iwaniec UT, Subramaniam M, Turner RT, Pitel KS, McGovern RM, Reid JM, Marler RJ, Ingle JN, Goetz MP, Hawse JR.

Endocrinology. 2017 Oct 1;158(10):3354-3368. doi: 10.1210/en.2016-1871.

40.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A.

J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2.

PMID:
28968163
41.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

42.

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.

Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP.

Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14.

43.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

44.

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM.

NPJ Breast Cancer. 2017 Aug 21;3:30. doi: 10.1038/s41523-017-0036-4. eCollection 2017.

45.

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.

Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN.

J Clin Oncol. 2017 Oct 20;35(30):3391-3400. doi: 10.1200/JCO.2017.73.3246. Epub 2017 Aug 30.

46.

Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.

Nguyen TT, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC.

Ann Surg Oncol. 2017 Oct;24(10):2989-2998. doi: 10.1245/s10434-017-5930-3. Epub 2017 Aug 1.

PMID:
28766214
47.

Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice.

Welsh JL, Hoskin TL, Day CN, Habermann EB, Goetz MP, Boughey JC.

Ann Surg Oncol. 2017 Oct;24(10):2881-2888. doi: 10.1245/s10434-017-5932-1. Epub 2017 Aug 1.

PMID:
28766197
48.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

49.

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP.

Cancer. 2017 Sep 15;123(18):3494-3501. doi: 10.1002/cncr.30766. Epub 2017 May 10.

50.

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

Haddad T, Qin R, Lupu R, Satele D, Eadens M, Goetz MP, Erlichman C, Molina J.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1221-1227. doi: 10.1007/s00280-017-3322-9. Epub 2017 May 5.

PMID:
28477227

Supplemental Content

Loading ...
Support Center